Why Intellia Therapeutics (NTLA) Is Down 13.8% After Positive Phase 3 HAE Gene-Editing Results And FDA Filing Simply Wall St 03:00 Wed, 29 Apr
Intellia Initiates Rolling BLA Submission for In Vivo CRISPR Therapy in Hereditary Angioedema JD Supra 19:04 Tue, 28 Apr
Can Intellia's Gene Editing Therapy Redefine Hae Care After Cutting Attacks By 87% In Phase 3? RTT News 02:15 Tue, 28 Apr
Intellia Heads To FDA With Positive Phase III Results For Lonvo-Z Scrip Pharma Intelligence 22:05 Mon, 27 Apr
Intellia Therapeutics Pops on CRISPR Trial Success. Does That Make NTLA Stock a Buy? Barchart 19:49 Mon, 27 Apr
Intellia’s in vivo gene therapy victorious in Phase III HAE trial Clinical Trials Arena 17:14 Mon, 27 Apr
Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder BioPharma Dive 15:17 Mon, 27 Apr
Intellia Therapeutics FDA Rolling Application For Gene Therapy Puts Hype To Test Benzinga 15:14 Mon, 27 Apr Article paywall
STAT Plus: Pharmalittle: We’re reading about a Lilly deal, an Intellia CRISPR rare-disease treatment, and more STAT 14:29 Mon, 27 Apr
Intellia Therapeutics Reports Positive Phase 3 Results For Hae Gene Therapy; Stock Up RTT News 13:25 Mon, 27 Apr
STAT Plus: Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial STAT 12:05 Mon, 27 Apr
Intellia To Report Phase 3 Haelo Topline Data For Lonvo-z On April 27; Stock Up RTT News 12:08 Sat, 25 Apr
Assessing Intellia Therapeutics (NTLA) Valuation After FDA Clears MAGNITUDE Trials And Analyst Upgrade Simply Wall St 10:41 Wed, 08 Apr
